Medicine for Malaria Venture (MMV)

Compartir

Title: 10th Call for proposals for Malaria Drug Discovery, Development and Clinical Capacity Building Projects

Title: MMV Challenge GrantTitle: 10th Call for proposals for Malaria Drug Discovery, Development and Clinical Capacity Building Projects

MMV welcomes proposals in the context of drug discovery and development or capacity building. MMV has identified four basic categories of indications for antimalarial treatment:
(a) The hits‐to‐lead stage for new families of molecules specifically addressing the key priorities of the malaria eradication agenda: transmission blocking and prevention of P. vivax relapse.
(b) Proposals for chemical series with the potential for P. falciparum chemoprevention or blood stage efficacy as a result of long‐half lives are encouraged, though the project should already have initial confirmation of in vivo oral blood stage activity.   Early target validation falls outside of our mandate.
(c) In the clinical arena, new chemical entities.
(d) Applications regarding capacity building to develop new sites for first‐in‐patient testing of these new molecules, including both blood stage, transmission blocking and P. Vivax anti‐relapse capabilities.
The prime area of interest for MMV is for agents that fall into the first category of affordable treatment for non‐severe malaria in children, pregnant women and adults as we currently see this as the area of greatest medical need. MMV’s ultimate goal is to be able to develop treatments that are completed with a single dose (certainly no more than once a day dosing for three days) so as to ensure patient compliance, have a low cost of goods and which are likely to have activity against artemisinin‐resistant strains

Deadline: Deadline for receipt of letters of intent March 15th, 2012

Further information: more information about the call and application procedure is available at http://www.mmv.org/research-development/10th-call-proposals

Title: MMV Challenge Grant

Proposals are expected to be at the concept stage (i.e. no prior experimental work is required) and to last no more than a year. These Challenge Grants will be prioritized based on scientific merit and according to the MMV strategy, and can constitute:
a)  Screening: testing the MMV Malaria Box against malaria and other parasitological assays
b)  Medicinal Chemistry: perform hit‐to‐lead or optimization chemistry on any anti‐malarial series
c)  Translational and Clinical Development: new methods to study or validate the inhibition of P.vivax relapses or the interruption of transmission
Number of Awards: 10 grants of 50000 USD each

Deadline: Deadline for receipt of letters of intent March 15th, 2012

Further information: more information about the call and application procedure is available at http://www.mmv.org/research-development/10th-call-proposals

Comentarios de Facebook